apg-115

Small moleculeexperimental

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • apg-115
  • apg-115

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06735820Phase 1/Phase 2 (Phase 2)Apr 1, 2025Georgetown University
NCT06654050Phase 2Nov 17, 2024National Cancer Institute (NCI)
NCT05701306Phase 1Mar 23, 2023Ascentage Pharma Group Inc., Government of China, Sun Yat-Sen University
NCT04785196Phase 1/Phase 2 (Phase 2)Jun 2, 2021Ascentage Pharma Group Inc., Government of China, Huazhong University of Science and Technology
NCT04358393Phase 1Jun 1, 2020Ascentage Pharma Group Inc.
NCT04275518Phase 1Feb 29, 2020Ascentage Pharma Group Inc., Chinese Academy of Medical Sciences
NCT03611868Phase 1/Phase 2 (Phase 2)Sep 15, 2018Ascentage Pharma Group Inc.
NCT02935907Phase 1Oct 1, 2016Ascentage Pharma Group Inc., South Texas Accelerated Research Therapeutics
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ascentage Pharma Group Inc.For profit6622016
Government of ChinaGovernment2022021
Chinese Academy of Medical SciencesAcademic/Hospital1012020
Georgetown UniversityAcademic/Hospital1112025
Huazhong University of Science and TechnologyAcademic/Hospital1012021
National Cancer Institute (NCI)Government1112024
South Texas Accelerated Research TherapeuticsFor profit1012016
Sun Yat-Sen UniversityAcademic/Hospital1012023
8 organizations
Page 1 / 1